Combination therapy with von Willebrand factor concentrate plus recombinant factor VIII during cesarean section in a patient with type 3 von Willebrand disease and a low inhibitor titer: a case report
Authors:
- 9 May 2022
- journal article
- case report
- Published by Springer Nature in International Journal of Hematology
- Vol. 116 (4) , 622-629
Abstract
Type 3 von Willebrand disease (VWD), a rare and severe subtype, can produce inhibitors in roughly 5% to 10% of cases. We present a case of type 3 VWD with inhibitors in late pregnancy, which was successfully managed with a combination of neutralization and factor (F)VIII replacement during cesarean delivery. The patient, a 30-year-old woman, had no history of inhibitors despite over 100 exposures to VWF/FVIII. She developed inhibitors after 28 weeks of weekly pd VWF/FVIII prophylaxis for recurrent urolithiasis-associated hematuria during pregnancy. Genetic analysis detected two novel frameshift mutations: VWF Exon7 c.777_784dup and Exon14 c.1625_1646del. Titers of inhibitors to factors VIII and VWF using the Bethesda assay were 1.2 and 1.1 BU/mL, respectively. Pharmacokinetics revealed significantly low in vivo recovery of FVIII:C and VWF:Rcof and shortened half-life. During cesarean delivery, a combination of bolus pd VWF/FVIII once daily for neutralizing inhibitors plus continuous infusion of recombinant FVIII Fc fusion protein resulted in minimal bleeding without allergic reactions. Both VWF:Rcof and FVIII:C levels increased transiently during the 7-h of combination therapy without thrombotic events. In conclusion, combination therapy with neutralization and continuous FVIII replacement was effective for hemostasis with a low VWD inhibitor titer, though further optimization is required.Keywords
This publication has 21 references indexed in Scilit:
- The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in HaematologyBritish Journal of Haematology, 2014
- Alloantibodies in von Willebrand diseaseBlood, 2013
- The challenging management of a child with type 3 von Willebrand disease and antibodies to von Willebrand factorHaemophilia, 2012
- Mutation distribution in the von Willebrand factor gene related to the different von Willebrand disease (VWD) types in a cohort of VWD patientsThrombosis and Haemostasis, 2012
- Management of delivery with FVIII/VWF concentrates in a pregnant woman with type 3 von Willebrand disease and alloantibodiesThrombosis and Haemostasis, 2012
- Italian Registry of Haemophilia and Allied Disorders. Objectives, methodology and data analysisHaemophilia, 2008
- Use of Recombinant Factor VIIa in Inherited and Acquired von Willebrand DiseaseClinical and Applied Thrombosis/Hemostasis, 2007
- Alloantibody from a patient with severe von Willebrand disease inhibits von Willebrand factor-FVIII interactionAnnals of Hematology, 1997
- Antibodies to von Willebrand factor in von Willebrand disease1995
- Life‐threatening reaction to factor VIII concentrate in a patient with severe von Willebrand disease and alloantibodies to von Willebrand factorEuropean Journal of Haematology, 1987